Key result
Systemic plasma levels of leptin (13.12 vs 7.34 ng/mL, P<0.05) and resistin (6.87 vs 4.4 ng/mL, P<0.05) were elevated in DCM patients vs controls and associated with heart failure progression.
Why the study?
Are high leptin and resistin plasma levels associated with adverse cardiac functional parameters and CHF progression in patients with DCM and DCMi?
Population
120 patients including a control group, patients with non-ischaemic dilated cardiomyopathy, and inflammatory…
Comparison
High leptin and resistin systemic plasma levels… vs Control group and low leptin/resistin plasma…
Design
Cohort
Follow-up
6 months
Authors
Loading...
May inform DCM prognosis; hypothesis-generating for adipokine targeting, needing prospective trials.
Observational (n=120)
Are high leptin and resistin plasma levels associated with adverse cardiac functional parameters and CHF progression in patients with DCM and DCMi?
High systemic levels of leptin and resistin are associated with worse cardiac function and heart failure progression in patients with dilated and inflammatory cardiomyopathy, potentially mediated by increased redox stress and inflammatory cytokine expression in cardiomyocytes.
Bobbert et al. (2012) conducted an observational in Chronic heart failure (dilated and inflammatory cardiomyopathy) (n=120). Leptin and resistin plasma levels vs. Control group / low plasma levels was evaluated on Cardiac functional parameters at 6-month follow-up. Systemic plasma levels of leptin (13.12 vs 7.34 ng/mL, P<0.05) and resistin (6.87 vs 4.4 ng/mL, P<0.05) were elevated in DCM patients vs controls and associated with heart failure progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: